AGLE-102

DRUG2 trials

Sponsors

Aegle Therapeutics

Conditions

BurnsDystrophic Epidermolysis Bullosa

Phase 1

MSC EVs in Dystrophic Epidermolysis Bullosa

RecruitingNCT04173650

Aegle TherapeuticsDystrophic Epidermolysis Bullosa

Start: 2024-08-13End: 2026-03-31Target: 8Updated: 2025-06-25

Safety of Extracellular Vesicles for Burn Wounds

CompletedNCT05078385

Aegle TherapeuticsBurns

Start: 2023-08-10End: 2024-11-19Updated: 2024-11-20